Brief: Data Published In Annals Of Oncology Reinforce Clinical Utility Of Veracyte’S Decipher Prostate Genomic Classifier For Informing Treatment Of Men Experiencing Prostate Cancer Progression
03/06/2022 13:31
June 3 (Reuters) - Veracyte Inc VCYT.O :
* DATA PUBLISHED IN ANNALS OF ONCOLOGY REINFORCE CLINICAL
UTILITY
OF VERACYTE’S DECIPHER PROSTATE GENOMIC CLASSIFIER FOR INFORMING
TREATMENT OF MEN EXPERIENCING PROSTATE CANCER PROGRESSION
Source text for Eikon: ID:nBw5YdTZWa
Further company coverage: VCYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina